Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: Selective action of human paraoxonase allozymes Q and R

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 18, Issue 10, 1998, Pages 1617-1624

  Aviram, Michael ^a,c   Billecke, Scott ^b   Sorenson, Robert ^b   Bisgaier, Charles ^b   Newton, Roger ^b   Rosenblat, Mira ^a   Erogul, John ^b   Hsu, Cary ^b   Dunlop, Cristina ^b   La Du, Bert ^b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Arylesterase; LDL; Lipid peroxidation; Paraoxonase; Sulfhydryl group

Indexed keywords

ALLOENZYME; ARYLESTERASE; LOW DENSITY LIPOPROTEIN;

AMINO ACID SEQUENCE; ARTICLE; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME PURIFICATION; GENETIC TRANSFECTION; LIPID OXIDATION; LIPID PEROXIDATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SITE DIRECTED MUTAGENESIS;

EID: 17344369784     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.18.10.1617     Document Type: Article

References (17)

1. La Du BN. Structural and functional diversity of paraoxonases. Nat Med. 1996;2:1186-1187.
2. La Du BN. Human serum paraoxonase/arylesterase. In: Kalow W, ed. Pharmacogenetics of Drug Metabolism. New York, NY: Pergamon Press; 1992:51-91.
3. La Du BN, Adkins S, Kuo CL, Lipsig D. Studies on human serum paraoxonase/arylesterase. Chem Biol Interact. 1993;87:25-34.
4. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol. 1996;7:69-76.
5. Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet. 1996;14:334-336.
6. Banka CL. High density lipoprotein and lipoprotein oxidation. Curr Opin Lipidol. 1996;7:139-142.
7. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoproteins in low-density lipoprotein. FEBS Lett. 1991;286: 152-154.
8. Mackness MI, Abbott C, Arrol S, Durrington PN. The role of highdensity lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J. 1993;294:829-834.
9. Mackness MI, Arrol S, Abbott CA, Durrington PN. Protection of lowdensity lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 1993;104:129-135.
10. Mackness MI, Durrington PN. HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis. 1995;115:243-253.
11. Navab M, Berliner JA, Watson AD, Hama SY, Teritto MC, Lusis AJ, Shih DM, Van Lenten BJ, Frank JS, Demer LL, Edwards PA, Fogelman AM. The yin and yang of oxidation in the development of the fatty streak: a review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol. 1996;16:831-842.
12. Watson AD, Berliner JA, Hama S Y, La Du BN, Fault KF, Fogelman AM, Navab M. Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidized lowdensity lipoprotein. J Clin Invest. 1995;96:2882-2891.
13. Shih DM, Gu L, Hama S, Xia YR, Navab M, Fogelman AM, Lusis AJ. Genetic dietary regulation of serum paraoxonase expression and its role in atherogenesis in mouse model. J Clin Invest. 1996;97:1630-1639.
14. Hegele RA, Brunt JH, Connelly PW. A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate. Arterioscler Thromb Vasc Biol. 1995;15:89-95.
15. Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol. 1995;15:1812-1818.
16. Mackness B, Hunt R, Durrington PN, Mackness MI. Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with progression of atherosclerosis. Arterioscler Thromb Vasc Biol. 1997;17:1233-1238.
17. McElveen J, Mackness MI, Colley CM, Peard T, Warner S, Walker CH. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin Chem. 1986;32:671-673.